STOCK TITAN

Daré Bioscience, Inc. - $DARE STOCK NEWS

Welcome to our dedicated page for Daré Bioscience news (Ticker: $DARE), a resource for investors and traders seeking the latest updates and insights on Daré Bioscience stock.

Daré Bioscience, Inc. (NASDAQ: DARE) is a clinical-stage biopharmaceutical company focused on the advancement of innovative products for women's reproductive health. The company's mission is to identify, develop, and bring to market a diverse portfolio of novel therapies that expand treatment options, improve outcomes, and facilitate convenience for women. Initially, the company's focus is on contraception, vaginal health, and fertility.

Daré's portfolio includes several product candidates in advanced clinical development. Their lead product, Ovaprene, is a non-hormonal monthly contraceptive ring currently undergoing clinical studies. The company's first FDA-approved product, XACIATO (clindamycin phosphate vaginal gel 2%), is a prescription gel for treating bacterial vaginosis in females aged 12 and older. Another prominent product candidate is Sildenafil Cream, 3.6%, a novel formulation intended to treat female sexual arousal disorder (FSAD).

Daré Bioscience has also engaged in significant partnerships to further its mission. For instance, the U.S. commercial rights for Ovaprene are licensed to Bayer, while XACIATO is under a global license agreement with Organon. This collaborative approach has enabled Daré to harness the clinical and market expertise of its partners while retaining control over development and regulatory approval processes.

Recently, Daré has aligned with the FDA on key elements of the Phase 3 program for Sildenafil Cream, setting the stage for a pivotal study to support a New Drug Application (NDA) filing. The company has also received grants, such as the $750,000 from the Bill & Melinda Gates Foundation, to support the development of bacteria-based biotherapeutic products. In addition, Daré is progressing with the clinical development of its hormonal therapy candidate, DARE-HRT1, a bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy.

Daré continues to build on its achievements from 2023, advancing its portfolio of novel investigational therapies, particularly those demonstrating proof of concept. The company actively engages in strategic processes to explore partnering opportunities for additional indications, such as GLP-1s for obesity and metabolic disorders.

Moreover, Daré received a $1 million payment as the latest installment under a grant agreement to advance its investigational contraceptive, DARE-LARC1. This product aims to address specific individual family planning goals with features like precision dosing and wireless control.

For the latest news and updates, investors and interested parties can visit Daré's investor relations website and follow their social media channels. The company remains committed to distributing material information through these channels and encourages stakeholders to stay informed about their developments and milestones.

Rhea-AI Summary

Daré Bioscience (NASDAQ: DARE) reported its Q1 2024 financials and company updates. Key developments include the ongoing Phase 3 study of Ovaprene®, a hormone-free contraceptive, and the successful end-of-Phase 2 meeting with the FDA for Sildenafil Cream, aimed at treating female sexual arousal disorder. Financial highlights show a decrease in Q1 2024 R&D expenses to $3.3 million from $5.0 million in Q1 2023, and a $22 million non-dilutive financing deal secured in April 2024. Cash reserves stood at $3.6 million as of March 31, 2024. The company's collaboration with Organon on XACIATO™ continues, with further milestones anticipated in 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.06%
Tags
-
Rhea-AI Summary

Daré Bioscience, Inc. will host a conference call and webcast on May 14, 2024, to discuss its financial results for Q1 2024. The company is a leader in women's health innovation, with details on how to access the call provided in the press release.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.31%
Tags
conferences earnings
-
Rhea-AI Summary

Daré Bioscience, Inc. (NASDAQ: DARE) has been chosen as a spoke member of the Investor Catalyst Hub, part of the nationwide ARPA-H network. This selection provides Daré with access to funding, networking opportunities, and the ability to influence research priorities in women's health.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.43%
Tags
none
Rhea-AI Summary

Daré Bioscience secured $22 million in non-dilutive strategic royalty financing to advance Phase 3 first-in-category women’s health product candidates through key catalysts. The transaction with XOMA provides significant capital for Daré to focus on advancing Ovaprene® and Sildenafil Cream, 3.6%. This accelerates potential cash flows and shareholder value, showcasing the company's commitment to delivering value for all stakeholders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.08%
Tags
-
Rhea-AI Summary
Daré Bioscience receives $1 million grant funding installment to advance development of DARE-LARC1 contraceptive technology. The potential contraceptive aims to offer women control over fertility with precision dosing, extended duration, and wireless control. The technology, developed by renowned researchers, has the potential to address unmet needs in reproductive health and other therapeutic areas like diabetes and obesity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.68%
Tags
none
-
Rhea-AI Summary
Daré Bioscience, Inc. announces positive results from postcoital test study of Ovaprene, a hormone-free monthly intravaginal contraceptive for women. The study demonstrated safety and efficacy, with Ovaprene preventing sperm entry without disrupting the vaginal microbiome. The pivotal Phase 3 clinical study is currently enrolling participants across the U.S. with the potential to support marketing approvals of Ovaprene in the future.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.71%
Tags
none
Rhea-AI Summary
Daré Bioscience, Inc. reported financial results for 2023, highlighting the availability of XACIATO™ for bacterial vaginosis treatment, progress on Ovaprene® contraceptive candidate Phase 3 study, and successful completion of end-of-Phase 2 meeting for Sildenafil Cream. The company is optimistic about achieving significant milestones in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.71%
Tags
-
Rhea-AI Summary
Daré Bioscience, Inc. (DARE) to host a conference call to discuss financial results for the year ended December 31, 2023, and provide a company update on March 28, 2024, at 4:30 p.m. Eastern Time. Investors can access the call via phone or live webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.61%
Tags
conferences earnings
-
Rhea-AI Summary
Daré Bioscience, Inc. (NASDAQ: DARE) reveals promising data from the Phase 2b RESPOND clinical study of Sildenafil Cream, 3.6%, showing increased sexual events frequency and improvements in various aspects of the sexual experience for women with female sexual arousal disorder. The company aims to move towards a Phase 3 pivotal study to address the lack of FDA-approved treatments for FSAD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.55%
Tags
conferences
Rhea-AI Summary
Daré Bioscience, Inc. (NASDAQ: DARE) and Strategic Science & Technologies, LLC announced the successful completion of an end-of-Phase 2 meeting with the FDA, supporting the advancement of Sildenafil Cream, 3.6% for the treatment of female sexual arousal disorder (FSAD) to a Phase 3 clinical study. The FDA confirmed that FSAD is an acceptable indication for the trials and that 12-weeks of blinded treatment may be acceptable. Positive data from the Phase 2b RESPOND clinical study supported the meeting, identifying the subgroup of patients most likely to benefit from therapy and achieve meaningful improvement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags

FAQ

What is Daré Bioscience's main focus?

Daré Bioscience focuses on developing innovative products for women's reproductive health, particularly in areas like contraception, vaginal health, and fertility.

What is Ovaprene?

Ovaprene is a non-hormonal, monthly contraceptive ring currently in clinical studies, aimed at providing a hormone-free birth control option for women.

Who are Daré Bioscience's key partners?

Daré Bioscience collaborates with partners like Bayer for Ovaprene's U.S. commercial rights and Organon for XACIATO, an FDA-approved vaginal gel for bacterial vaginosis.

What is Sildenafil Cream, 3.6% used for?

Sildenafil Cream, 3.6% is an investigational cream formulation designed to treat female sexual arousal disorder (FSAD).

What is XACIATO?

XACIATO is an FDA-approved clindamycin phosphate vaginal gel for treating bacterial vaginosis in females aged 12 and older.

What are some recent achievements of Daré Bioscience?

Recent achievements include the FDA approval of XACIATO, the advancement of Ovaprene into Phase 3 studies, and progress towards a Phase 3 trial for Sildenafil Cream.

What grant support has Daré Bioscience received?

Daré received a $750,000 grant from the Bill & Melinda Gates Foundation to support the development of bacteria-based biotherapeutic products.

What is DARE-LARC1?

DARE-LARC1 is an investigational long-acting, reversible contraceptive that features precision dosing, extended device duration, and wireless control.

How does Daré Bioscience distribute material information?

Daré distributes material information through its investor relations website, SEC filings, press releases, public conference calls, webcasts, and social media channels.

What is the company's mission?

Daré Bioscience aims to advance innovative products that expand treatment options, improve outcomes, and facilitate convenience for women, primarily in the areas of contraception, vaginal health, and fertility.

Daré Bioscience, Inc.

Nasdaq:DARE

DARE Rankings

DARE Stock Data

45.47M
98.89M
1.65%
6.63%
0.23%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
SAN DIEGO